{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:07:13Z","timestamp":1792433233145,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006003","name":"CSIC General Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["54211793"],"award-info":[{"award-number":["54211793"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["IR2021-UVA04"],"award-info":[{"award-number":["IR2021-UVA04"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["IR2020-1-UVA01"],"award-info":[{"award-number":["IR2020-1-UVA01"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-148270OB-I00"],"award-info":[{"award-number":["PID2023-148270OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtauto.2025.100271","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:47:25Z","timestamp":1737546445000},"page":"100271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4470-075X","authenticated-orcid":false,"given":"Elisa","family":"Arribas-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"De Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-8932","authenticated-orcid":false,"given":"Beatriz","family":"de Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-6003","authenticated-orcid":false,"given":"Benito","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-3921","authenticated-orcid":false,"given":"Jes\u00fas","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Garc\u00eda-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mart\u00edn-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Garrote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fern\u00e1ndez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2025.100271_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1057","article-title":"Anatomical basis of tolerance and immunity to intestinal antigens","volume":"3","author":"Mowat","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100271_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2025.100271_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrgastro.2014.201","article-title":"IBD pathogenesis in 2014 : molecular pathways controlling barrier function in IBD","volume":"12","author":"Atreya","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jtauto.2025.100271_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","article-title":"Update on Janus kinase antagonists in inflammatory bowel disease","volume":"43","author":"Boland","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jtauto.2025.100271_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jtauto.2025.100271_bib6","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100271_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2025.100271_bib8","first-page":"70","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"13","author":"Balzola","year":"2012","journal-title":"Inflammatory Bowel Disease Monitor"},{"key":"10.1016\/j.jtauto.2025.100271_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm."},{"key":"10.1016\/j.jtauto.2025.100271_bib10","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2005-02-0769","article-title":"Jak3 negatively regulates dendritic-cell cytokine production and survival","volume":"106","author":"Yamaoka","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2025.100271_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007066","article-title":"Jak3 is involved in dendritic cell maturation and CCR7-dependent migration","volume":"4","author":"Rivas-Caicedo","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jtauto.2025.100271_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1160719","article-title":"Advances in the role of STAT3 in macrophage polarization","volume":"14","author":"Xia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100271_bib13","doi-asserted-by":"crossref","first-page":"12442","DOI":"10.1073\/pnas.1816410116","article-title":"JAK\/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors","volume":"116","author":"Irey","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtauto.2025.100271_bib14","first-page":"69","author":"Arribas-Rodriguez","year":"2023","journal-title":"Study and isolation of human intestinal dendritic cell and macrophage subsets"},{"key":"10.1016\/j.jtauto.2025.100271_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41385-018-0030-7","article-title":"Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c-CCR2-CX3CR1- counterparts, are expanded in inflammatory bowel disease article","volume":"11","author":"Bernardo","year":"2018","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jtauto.2025.100271_bib16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/gut.52.10.1522","article-title":"The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria","volume":"52","author":"Stagg","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jtauto.2025.100271_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700931","article-title":"Human intestinal dendritic cells in inflammatory bowel diseases","volume":"62","author":"Bernardo","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.jtauto.2025.100271_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/mnfr.201300596","article-title":"Altered human gut dendritic cell properties in ulcerative colitis are reversed by Lactobacillus plantarum extracellular encrypted peptide STp","volume":"58","author":"Al-Hassi","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.jtauto.2025.100271_bib19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/MIB.0000000000000223","article-title":"Human gut dendritic cells drive aberrant gut-specific T-cell responses in ulcerative colitis, characterized by increased IL-4 production and loss of IL-22 and IFN\u03b3","volume":"20","author":"Mann","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jtauto.2025.100271_bib20","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100271_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/exd.14059","article-title":"The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development","volume":"29","author":"Stalder","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jtauto.2025.100271_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1189\/jlb.1A0114-058RR","article-title":"Human blood CD1c dendritic cells stimulate IL-12-independent IFN- \u03b3 responses and have a strikingly low inflammatory profile","volume":"97","author":"Benlahrech","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtauto.2025.100271_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1055914","article-title":"The role of Th17 cells in inflammatory bowel disease and the research progress","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100271_bib24","first-page":"383","article-title":"Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics","volume":"13","author":"Texler","year":"2022","journal-title":"CMGH"},{"key":"10.1016\/j.jtauto.2025.100271_bib25","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00383.2020","article-title":"Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1\/3 reduction in T-cells","volume":"320","author":"Brand","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jtauto.2025.100271_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00018-024-05196-1","article-title":"Macrophage re-programming by JAK inhibitors relies on MAFB","volume":"81","author":"L\u00f3pez-Navarro","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jtauto.2025.100271_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002671","article-title":"JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation","volume":"9","author":"Nyirenda","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jtauto.2025.100271_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ibd\/izz213","article-title":"Tofacitinib reprograms human monocytes of IBD patients and healthy controls toward a more regulatory phenotype","volume":"26","author":"Cordes","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jtauto.2025.100271_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jid.2021.07.180","article-title":"Tofacitinib suppresses IL-10\/IL-10r signaling and modulates host defense responses in human macrophages","volume":"142","author":"Knoke","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jtauto.2025.100271_bib30","article-title":"State-of-the-art cytometry in the search of novel biomarkers in digestive cancers","volume":"14","author":"de Castro C","year":"2024","journal-title":"Front. Oncol."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:56:17Z","timestamp":1750892177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909025000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S2589909025000061"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100271","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100271"}}